The CD30 antigen is significantly present in the tumors of Hodgkin lymphoma and anaplastic large cell lymphoma; as such this antibody-drug conjugate is effective and specific for treating these disease entities [4]. This evidence concerns the gene TNFRSF8 and anaplastic large cell lymphoma.